Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Pharmacokinetics of MDV3100 × enzalutamide × 90 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 42 Prostatic Neoplasms, Castration-Resistant 5 Neoplasms 4 Neoplasm Metastasis 4 Metastatic Castration-Resistant Prostate Cancer 3 Small Cell Lung Carcinoma 2 Recurrence 2 Metastatic Hormone-sensitive Prostate Cancer 2 mCRPC 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Cancer 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Primary Dysautonomias 1 Pathologic Complete Response 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasm, Residual 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Lymphoma, Follicular 1 Kidney Diseases 1 Hypertension 1 Dementia 1 Colorectal Neoplasms 1 Cognitive Dysfunction 1 Carcinoma, Small Cell 1 Carcinoma, Non-Small-Cell Lung 1 Bulbo-Spinal Atrophy, X-Linked 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡